LEGN Share Price Performance
US$27.71
-14.36 (-34.13%)
49.5% undervalued intrinsic discount
US$54.82
Fair Value
Price US$27.71
AnalystLowTarget US$54.82
AnalystConsensusTarget US$74.91
AnalystHighTarget US$94.00
Fair ValueUS$54.82
Share Pricen/a
Legend Biotech Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 39 Fair Values set on narratives written by author
LEGN Community Narratives
AN
Fair Value US$54.82 49.5% undervalued intrinsic discount
Price Controls And Competitive Risks Will Challenge Cell Therapy Recovery
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$74.91 63.0% undervalued intrinsic discount
Market Momentum and Global Listing Plans Will Drive Significant Upside Potential
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$94 70.5% undervalued intrinsic discount
CAR-T Advancements Will Expand Global Cancer Therapy Access
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Market Momentum and Global Listing Plans Will Drive Significant Upside Potential
Key Takeaways Solid pipeline and regulatory tailwinds drive expanded patient access, wider adoption, and long-term revenue growth in multiple myeloma therapies. Global roll-out and scaling production enhance operating leverage, broaden market reach, and improve margins while maintaining competitive advantage with innovative CAR-T technologies.Read more
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$74.91
63.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
39% p.a.
Profit Margin
29.33%
Future PE
24.14x
Price in 2028
US$91.76
CAR-T Advancements Will Expand Global Cancer Therapy Access
Key Takeaways Rapid adoption and strong clinical data position CARVYKTI for accelerated growth, with potential to exceed conservative market expectations and drive sustained topline momentum. Pipeline diversity, manufacturing expansions, and favorable policy shifts could unlock multi-segment revenue, margin expansion, and stronger international presence.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$94
70.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
55% p.a.
Profit Margin
31.17%
Future PE
23x
Price in 2028
US$113.84
Price Controls And Competitive Risks Will Challenge Cell Therapy Recovery
Key Takeaways Heightened competition, pricing pressures, and reimbursement scrutiny threaten revenue growth and limit predictability despite rising global demand for cell therapies. Heavy dependence on CARVYKTI and significant R&D spending expose Legend to concentration risk and continued margin pressures in a rapidly evolving treatment landscape.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$54.82
49.5% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
37% p.a.
Profit Margin
12.28%
Future PE
49.12x
Price in 2028
US$66.4
Trending Discussion
Recently Updated Narratives
AN
LEGN: Global Listing Pursuits Will Drive Future Market Expansion
Fair Value: US$74.91 63.0% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Price Controls And Competitive Risks Will Challenge Cell Therapy Recovery
Fair Value: US$54.82 49.5% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CAR-T Advancements Will Expand Global Cancer Therapy Access
Fair Value: US$94 70.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Legend Biotech Corporation Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.30
- 14.60%
- -26.37%
- 31.1%
About LEGN
- Founded
- 2014
- Employees
- 2900
- CEO
- WebsiteView website
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
